COMMUNIQUÉS West-GlobeNewswire

Data Collected by Exalenz Bioscience in Galectin Therapeutics’ Phase 2 NASH-CX Trial of GR-MD-02 to Be Presented at AASLD Annual Meeting
05/11/2018
NORCROSS, Ga., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that an abstract based on results obtained [...]
Spero Therapeutics Announces Positive Results from SPR720 IND-Enabling Studies and Plans to Initiate a Phase 1 Trial
05/11/2018
CAMBRIDGE, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments [...]
AIT Therapeutics to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum
05/11/2018
GARDEN CITY, N.Y. and REHOVOT, Israel, Nov. 05, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTCQB: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO [...]
Spring Bank Pharmaceuticals, Inc. to Present at Upcoming Healthcare Conferences
05/11/2018
HOPKINTON, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, [...]
Samumed Announces Multiple Presentations at 6th World Congress on Controversies, Debates & Consensus in Bone, Muscle & Joint Diseases (BMJD)
05/11/2018
SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that it will present clinical and preclinical data on the company’s small molecule Wnt pathway inhibitor, SM04690, in four poster presentations [...]
Rexahn Reports Third Quarter 2018 Financial Results
05/11/2018
ROCKVILLE, Md., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, [...]
Opiant Pharmaceuticals Announces Last Patient, Last Visit in Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa
05/11/2018
Top-line Results Expected in First Quarter of 2019 SANTA MONICA, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological [...]
Krystal Biotech Reports Third Quarter 2018 Financial Results and Provides Corporate Update
05/11/2018
Announced positive interim results from randomized placebo-controlled Phase 1/2 clinical study of KB103, a first-in-class topical gene therapy for the treatment of dystrophic epidermolysis bullosa PITTSBURGH, Nov. 05, [...]
Pascal Biosciences Announces Optimization of Cannabinoid-Derived Drug Candidates to Kill Glioblastoma Cells
05/11/2018
VANCOUVER, British Columbia and SEATTLE, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced the peer reviewed [...]
Transactions under Novozymes’ stock buyback program
05/11/2018
Please read the full announcement in the attached PDF Attachment 2018_62_Stock_Buybackprogram_EN
Elite Pharmaceuticals Launches Generic Methadone Tablets
05/11/2018
NORTHVALE, N.J., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, [...]
Minerva Neurosciences Reports Third Quarter 2018 Financial Results and Business Updates
05/11/2018
Data readouts from five ongoing late-stage trials expected in 2019 WALTHAM, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the [...]
Metacrine to Present Rapid Efficacy of MET409 in a NASH Mouse Model at The Liver Meeting 2018
05/11/2018
SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, [...]
FDA Approves Novel Single-Vial Formulation of EGRIFTA®
05/11/2018
MONTREAL, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that the Food and Drug Administration in the United States has approved the new single-vial [...]
La FDA approuve la nouvelle formulation d’EGRIFTA(MD) en fiole unique
05/11/2018
MONTRÉAL, 05 nov. 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) est heureuse d’annoncer que la Food and Drug Administration aux États-Unis a approuvé la nouvelle formulation en fiole [...]
Kura Oncology Initiates Registration-Directed Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinomas
05/11/2018
– AIM-HN designed to enroll at least 59 patients with HRAS mutant HNSCC – – Full enrollment expected in two years with response rate as primary endpoint – SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc [...]
Radient Technologies Inc. Appoints Mr. Christian Aigner as Managing Director, Germany, and Announces European and Canadian Plant Expansions
05/11/2018
EDMONTON, Alberta, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) ( TSX Venture: RTI ) is pleased to announce it has appointed Mr. Christian Aigner to the position of Managing [...]
Release date of nine-month interim report (Q3) 2018 and audio cast
05/11/2018
On Friday, 9 November 2018, ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ) releases its interim report for the six months ended 30 September 2018. ALK will host a meeting for analysts and institutional investors that day [...]
Myriad Receives the Prestigious 2018 Utah Top Workplaces Award
05/11/2018
SALT LAKE CITY, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced its recognition as a 2018 recipient of the Utah Top [...]

Pages